The Protocole
The Protocole is a venture-backed clinical peptide platform that emerged from stealth in April 2026 with a $6 million seed round led by Rare Capital. Rather than a-la-carte prescribing, The Protocole builds personalized multi-peptide protocols around health goals (Youth, Focus, Sculpt, Rebuild). Access is invite-only with $60/month membership, quarterly recalibration consults, and unlimited care team messaging.
Overview
- Consultation Model
- Hybrid
- Headquarters
- Remote
- Shipping
- Expedited delivery included
- Lab Testing
- No
- Prescriber Info
- Licensed clinicians design personalized multi-peptide protocols with quarterly recalibration
- Founded
- 2025
Pros
- Personalized multi-peptide protocol design (not cookie-cutter prescribing)
- Strong VC backing ($6M seed from Rare Capital)
- Affordable membership fee ($60/month) with no upfront commitment
- All peptides from FDA-registered US pharmacies with >99% purity testing
- Concierge-level care (quarterly recalibrations, unlimited messaging)
Cons
- Brand new (founded 2025, launched April 2026) — no patient outcome data
- Invite/referral-only model limits accessibility
- No public reviews on Trustpilot, Google, or BBB
- Smaller current peptide menu (7 compounds)
Pricing
| Medication | Dose | Price | Billing |
|---|---|---|---|
| bpc-157 | standard vial (4–6 week supply) | $200 | per-vial |
| semaglutide | standard vial (4–6 week supply) | $200 | per-vial |